MX2019005782A - Prevencion y/o tratamiento de lesion aguda de riñon inducida por contraste. - Google Patents
Prevencion y/o tratamiento de lesion aguda de riñon inducida por contraste.Info
- Publication number
- MX2019005782A MX2019005782A MX2019005782A MX2019005782A MX2019005782A MX 2019005782 A MX2019005782 A MX 2019005782A MX 2019005782 A MX2019005782 A MX 2019005782A MX 2019005782 A MX2019005782 A MX 2019005782A MX 2019005782 A MX2019005782 A MX 2019005782A
- Authority
- MX
- Mexico
- Prior art keywords
- kidney injury
- contrast
- acute kidney
- induced acute
- prevention
- Prior art date
Links
- 208000009304 Acute Kidney Injury Diseases 0.000 title abstract 4
- 208000033626 Renal failure acute Diseases 0.000 title abstract 4
- 201000011040 acute kidney failure Diseases 0.000 title abstract 4
- 230000002265 prevention Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229960001177 trimetazidine Drugs 0.000 abstract 2
- DZLOHEOHWICNIL-QGZVFWFLSA-N (2R)-2-[6-(4-chlorophenoxy)hexyl]-2-oxiranecarboxylic acid ethyl ester Chemical compound C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)OCC)CO1 DZLOHEOHWICNIL-QGZVFWFLSA-N 0.000 abstract 1
- LJCWONGJFPCTTL-ZETCQYMHSA-N L-4-hydroxyphenylglycine Chemical compound OC(=O)[C@@H](N)C1=CC=C(O)C=C1 LJCWONGJFPCTTL-ZETCQYMHSA-N 0.000 abstract 1
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229950006213 etomoxir Drugs 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229960002937 meldonium Drugs 0.000 abstract 1
- PVBQYTCFVWZSJK-UHFFFAOYSA-N meldonium Chemical compound C[N+](C)(C)NCCC([O-])=O PVBQYTCFVWZSJK-UHFFFAOYSA-N 0.000 abstract 1
- 229950010617 oxfenicine Drugs 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- CYXKNKQEMFBLER-UHFFFAOYSA-N perhexiline Chemical compound C1CCCNC1CC(C1CCCCC1)C1CCCCC1 CYXKNKQEMFBLER-UHFFFAOYSA-N 0.000 abstract 1
- 229960000989 perhexiline Drugs 0.000 abstract 1
- 229960000213 ranolazine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan métodos para prevenir, reducir y/o tratar lesión aguda de riñón inducida por contraste, los cuales incluyen administrar un inhibidor de oxidación de ácidos grasos a un paciente en necesidad de lo mismo. También se proporcionan métodos que involucran el uso de trimetazidina o sales farmacéuticamente aceptables de la misma para la prevención y/o tratamiento de lesión aguda de riñón inducida por contraste. También se proporcionan métodos para prevenir y/o tratar lesión aguda de riñón inducida por contraste, los cuales incluyen administración de uno o más de trimetazidina, etomoxir, oxfenicina, perhexilina, mildronato o ranolazina o una sal farmacéuticamente aceptable de cualquiera de los precedentes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662424771P | 2016-11-21 | 2016-11-21 | |
| PCT/US2017/062771 WO2018094387A1 (en) | 2016-11-21 | 2017-11-21 | Prevention and/or treatment of contrast-induced acute kidney injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019005782A true MX2019005782A (es) | 2019-08-29 |
Family
ID=62144125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019005782A MX2019005782A (es) | 2016-11-21 | 2017-11-21 | Prevencion y/o tratamiento de lesion aguda de riñon inducida por contraste. |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US11123345B2 (es) |
| EP (2) | EP4378457A3 (es) |
| JP (3) | JP7474463B2 (es) |
| CA (1) | CA3044270A1 (es) |
| MX (1) | MX2019005782A (es) |
| WO (1) | WO2018094387A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11123345B2 (en) | 2016-11-21 | 2021-09-21 | Saghmos Therapeutics, Inc. | Prevention and/or treatment of contrast-induced acute kidney injury |
| WO2019161309A1 (en) * | 2018-02-19 | 2019-08-22 | Martin Pharmaceuticals Inc. | Stable oral liquid formulation of trimetazidine |
| WO2025137462A1 (en) * | 2023-12-21 | 2025-06-26 | Numiera Therapeutics Inc. | Combination therapy for cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2490963B1 (fr) * | 1980-09-30 | 1986-04-18 | Science Union & Cie | Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine |
| US20080059228A1 (en) | 2004-04-24 | 2008-03-06 | Christopher Bossi | Operation Of A Remote Medication Management System |
| WO2008057534A2 (en) * | 2006-11-07 | 2008-05-15 | University Of Vermont And State Agricultural College | Methods and compositions for organ protection |
| CA2679975A1 (en) | 2007-03-09 | 2008-09-18 | Symcopeia Company | Therapy for hyperglycemia, related disorders and erectile dysfunction |
| WO2009066315A2 (en) * | 2007-08-08 | 2009-05-28 | Usv Limited | Sustained release compositions of trimetazidine and process for preparation thereof |
| EP2200591A2 (en) | 2007-09-11 | 2010-06-30 | Ranbaxy Laboratories Limited | Controlled release pharmaceutical dosage forms of trimetazidine |
| WO2009088860A2 (en) * | 2007-12-31 | 2009-07-16 | Inotek Pharmaceuticals Corporation | A method of preventing contrast-induced nephropathy |
| EP3741381B1 (en) | 2008-02-26 | 2024-04-24 | Cornell University | A peptide for use for prevention and treatment of acute renal injury |
| US20110091427A1 (en) | 2009-10-02 | 2011-04-21 | Baxter International Inc. | Methods for treating a kidney injury |
| US9271952B2 (en) | 2011-10-11 | 2016-03-01 | Complexa, Inc. | Compositions and methods for treating nephropathy |
| FR2986431B1 (fr) * | 2012-02-03 | 2017-03-17 | Servier Lab | Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques |
| US11123345B2 (en) | 2016-11-21 | 2021-09-21 | Saghmos Therapeutics, Inc. | Prevention and/or treatment of contrast-induced acute kidney injury |
| US20180190374A1 (en) | 2017-01-03 | 2018-07-05 | Saghmos Therapeutics, Inc. | Methods of improving patient compliance to treat contrast-induced injury |
-
2017
- 2017-11-21 US US16/462,789 patent/US11123345B2/en active Active
- 2017-11-21 US US15/819,591 patent/US20180140599A1/en not_active Abandoned
- 2017-11-21 MX MX2019005782A patent/MX2019005782A/es unknown
- 2017-11-21 WO PCT/US2017/062771 patent/WO2018094387A1/en not_active Ceased
- 2017-11-21 EP EP24155776.8A patent/EP4378457A3/en active Pending
- 2017-11-21 CA CA3044270A patent/CA3044270A1/en active Pending
- 2017-11-21 JP JP2019547594A patent/JP7474463B2/ja active Active
- 2017-11-21 EP EP17872053.8A patent/EP3525771A4/en not_active Withdrawn
-
2021
- 2021-09-14 US US17/475,212 patent/US11986473B2/en active Active
-
2022
- 2022-02-17 JP JP2022022785A patent/JP2022059054A/ja active Pending
-
2024
- 2024-01-26 JP JP2024010111A patent/JP2024028652A/ja active Pending
- 2024-04-05 US US18/627,978 patent/US20250073227A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3525771A1 (en) | 2019-08-21 |
| JP2019535830A (ja) | 2019-12-12 |
| JP2024028652A (ja) | 2024-03-04 |
| JP2022059054A (ja) | 2022-04-12 |
| EP3525771A4 (en) | 2020-05-27 |
| US20190365740A1 (en) | 2019-12-05 |
| JP7474463B2 (ja) | 2024-04-25 |
| US20210401832A1 (en) | 2021-12-30 |
| US20180140599A1 (en) | 2018-05-24 |
| EP4378457A2 (en) | 2024-06-05 |
| US11986473B2 (en) | 2024-05-21 |
| EP4378457A3 (en) | 2024-07-31 |
| US11123345B2 (en) | 2021-09-21 |
| CA3044270A1 (en) | 2018-05-24 |
| WO2018094387A1 (en) | 2018-05-24 |
| US20250073227A1 (en) | 2025-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY201629A (en) | Benzopyrazole compounds and analogues thereof | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| PH12016502256A1 (en) | Medical use | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| WO2015160975A3 (en) | Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer | |
| MY189333A (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| MX382162B (es) | Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer. | |
| PH12017500933A1 (en) | Sublingual administration of riluzole | |
| MX365366B (es) | Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné. | |
| MX2017012123A (es) | Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer. | |
| PH12017500934A1 (en) | Sublingual formulation of riluzole | |
| MX383254B (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
| CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| MX2019005782A (es) | Prevencion y/o tratamiento de lesion aguda de riñon inducida por contraste. | |
| CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| PT3215143T (pt) | Combinação compreendendo espirulina e palmitoíletanolamida | |
| PH12016502107A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
| AR099490A1 (es) | Métodos terapéuticos en los que se emplea noribogaína y compuestos relacionados | |
| UA98964U (ru) | Способ медико-психологической помощи больным сосудистой деменцией | |
| HK1231763A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders |